Article
Oncology
Cecile Torregrosa, Simon Pernot, Pauline Vaflard, Audrey Perret, Christophe Tournigand, Violaine Randrian, Solene Doat, Cindy Neuzillet, Valerie Moulin, Morgane Stouvenot, Gael Roth, Tiffany Darbas, Benjamin Auberger, Tiphaine Godet, Marion Jaffrelot, Aurelien Lambert, Olivier Dubreuil, Cassandre Gluszak, Alice Bernard-Tessier, Anthony Turpin, Lola-Jade Palmieri, Olivier Bouche, Gael Goujon, Thierry Lecomte, David Sefrioui, Christophe Locher, Lucien Grados, Pauline Gignoux, Stephanie Trager, Elise Nassif, Angelique Saint, Pascal Hammel, Cedric Lecaille, Mathilde Bureau, Marine Perrier, Damien Botsen, Vincent Bourgeois, Julien Taieb, Edouard Auclin
Summary: In second-line treatment, for patients with metastatic colorectal cancer, the combination of FOLFIRI and bevacizumab is associated with longer overall survival and progression-free survival compared to the combination of FOLFIRI and aflibercept.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Marinde J. G. Bond, Babette I. Kuiper, Karen Bolhuis, Aysun Komurcu, Martinus J. van Amerongen, Thiery Chapelle, Cornelis H. C. Dejong, Marc R. W. Engelbrecht, Michael F. Gerhards, Dirk J. Grunhagen, Thomas van Gulik, John J. Hermans, Koert P. de Jong, Joost M. Klaase, Niels F. M. Kok, Wouter K. G. Leclercq, Mike S. L. Liem, Krijn P. van Lienden, I. Quintus Molenaar, Ulf P. Neumann, Gijs A. Patijn, Arjen M. Rijken, Theo M. Ruers, Cornelis Verhoef, Johannes H. W. de Wilt, Geert Kazemier, Anne M. May, Cornelis J. A. Punt, Rutger-Jan Swijnenburg
Summary: This study evaluated the variability in assessing resectability and local treatment planning for patients with initially unresectable colorectal cancer liver metastases. The results showed differences and disagreements in the evaluations, highlighting the need for consensus guidelines to prevent unwarranted variability in clinical practice.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Immunology
Siyuan Weng, Zaoqu Liu, Xiaofeng Ren, Hui Xu, Xiaoyong Ge, Yuqing Ren, Yuyuan Zhang, Qin Dang, Long Liu, Chunguang Guo, Richard Beatson, Jinhai Deng, Xinwei Han
Summary: The study identified that the SCG2 gene is closely associated with the chemotherapy response in colorectal cancer patients, with high expression predicting poorer prognosis and showing significantly higher expression in the APC non-mutation group. The SCG2 high expression subgroup is more suitable for immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Robert W. Holloway, Alberto A. Mendivil, James E. Kendrick, Lisa N. Abaid, John V. Brown, Jane LeBlanc, Nathalie D. McKenzie, Kristina M. Mori, Sarfraz Ahmad
Summary: The study evaluated the antitumor activity and safety of Olvi-Vec virotherapy combined with platinum-based chemotherapy in patients with advanced ovarian cancer. The results showed promising efficacy and tolerability of this treatment regimen, providing a basis for further clinical investigations.
Article
Oncology
Qin Xu, Junjie Wang, Yang Sun, Yibin Lin, Jing Liu, Yanhong Zhuo, Zhangzhou Huang, Songhua Huang, Ying Chen, Li Chen, Meifang Ke, Li Li, Zirong Li, Junping Pan, Yanwen Song, Rongqiang Liu, Chuanben Chen
Summary: This study investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1-positive advanced cervical cancer patients. The results showed a high objective response rate and disease control rate of sintilimab plus anlotinib in these patients, along with a certain proportion of treatment-related adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Immunology
Siyuan Weng, Zaoqu Liu, Hui Xu, Xiaoyong Ge, Yuqing Ren, Qin Dang, Long Liu, Jian Zhang, Peng Luo, Jianzhuang Ren, Xinwei Han
Summary: In this study, we identified ALOX12 as a key gene associated with bevacizumab response in colorectal cancer through weighted gene co-expression network analysis and receiver operating characteristic curve analysis. Further research revealed that ALOX12 was closely related to prognosis, tumor proliferation, invasion, and metastasis in colorectal cancer. Additionally, high ALOX12 expression predicted higher immune infiltration and better immunotherapy response.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yan Lin, Xiaoli Liao, Yumei Zhang, Guobin Wu, Jiazhou Ye, Shanshan Luo, Xinxin He, Min Luo, Mingzhi Xie, Jinyan Zhang, Qian Li, Yu Huang, Sina Liao, Yongqiang Li, Rong Liang
Summary: This study suggests that the mutant type (HR-MUT) of the Homologous recombination (HR) pathway may impact the chemotherapy sensitivity and prognosis of colorectal cancer (CRC) patients. HR-MUT patients have a lower probability of tumor metastasis after chemotherapy, and HR-MUT can be used as an independent predictor of chemotherapy prognosis for CRC patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Genetics & Heredity
Yali Liu, Harry Cheuk-Hay Lau, Wing Yin Cheng, Jun Yu
Summary: Colorectal cancer (CRC) is a common and deadly form of cancer, with both genetic and environmental factors playing a role in its development. Dysbiosis in the gut microbiome has been identified as a risk factor for CRC. Recent data has shown that the gut microbiome is directly involved in DNA damage, inflammation, and drug resistance in CRC, suggesting that modulating the gut microbiome could be a powerful tool in prevention and therapy. This article provides an overview of the relationship between the gut microbiome and CRC, explores the mechanisms of colorectal tumorigenesis, and discusses the potential of bacterial species as clinical biomarkers.
GENOMICS PROTEOMICS & BIOINFORMATICS
(2023)
Article
Oncology
Hiroya Taniguchi, Kentaro Yamazaki, Toshiki Masuishi, Takeshi Kawakami, Yusuke Onozawa, Kazunori Honda, Shigenori Kadowaki, Yukiya Narita, Takahiro Tsushima, Satoshi Hamauchi, Akiko Todaka, Tomoya Yokota, Masashi Ando, Keita Mori, Hiromichi Shirasu, Hirofumi Yasui, Kei Muro
Summary: In this phase Ib study, trifluridine/tipiracil, irinotecan, and bevacizumab were tested in patients with metastatic colorectal cancer. The treatment showed moderate antitumor activity but had a high risk of severe myelotoxicity.
Article
Oncology
Marinde J. G. Bond, Karen Bolhuis, Olaf J. L. Loosveld, Jan Willem B. de Groot, Helga Droogendijk, Helgi H. Helgason, Mathijs P. Hendriks, Joost M. Klaase, Geert Kazemier, Mike S. L. Liem, Arjen M. Rijken, Cornelis Verhoef, Johannes H. W. de Wilt, Koert P. Jong, Michael F. Gerhards, Martinus J. van Amerongen, Marc R. W. Engelbrecht, Krijn P. van Lienden, I. Quintus Molenaar, Bart de Valk, Brigitte C. M. Haberkorn, Emile D. Kerver, Frans Erdkamp, Robbert J. van Alphen, Danielle Mathijssen-van Stein, Aysun Komurcu, Marta Lopez-Yurda, Rutger-Jan Swijnenburg, Cornelis J. A. Punt, Dutch Colorectal Canc Study Grp
Summary: This study compared the efficacy of different induction regimens in patients with initially unresectable colorectal cancer liver metastases. The results showed that FOLFOXIRI-bevacizumab was the preferred treatment for patients with right-sided primary tumor or RAS/BRAFV600E mutation, while the addition of panitumumab to FOLFOX or FOLFIRI in patients with left-sided and RAS/BRAFV600E wild-type tumor showed no clinical benefit but more toxicity.
Article
Oncology
Pamela Baldin, Javier Carrasco, Gabriela Beniuga, Anne Jouret-Mourin, Gauthier Demolin, Sandrine Roland, Lionel D'Hondt, Philippe Vergauwe, Daniel Van Daele, Marie Mailleux, Isabelle Sinapi, Astrid De Cuyper, Noella Bletard, Brigitte Massart, Monique Delos, Marie-Laure Castella, Aline van Maanen, Marc Van den Eynde
Summary: This prospective trial recruited 65 patients with resectable colorectal liver metastases and found that preoperative chemotherapy did not significantly affect the pathological response rate, but confirmed pathological response as an important prognostic factor.
Article
Oncology
Toshimitsu Tanaka, Hiroyuki Suzuki, Tomoyuki Ushijima, Sachiko Nagasu, Yoshito Akagi, Takumi Kawaguchi, Keisuke Miwa
Summary: This study provides evidence that FOLFIRI plus bevacizumab therapy is a safe and efficient treatment option for patients undergoing hemodialysis with unresectable CRC, and it also suggests that the changes in serum bevacizumab concentration in these patients are similar to those with normal renal function.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Medicine, General & Internal
Oladapo O. Yeku, Dan L. Longo
Summary: This editorial discusses the scientific basis of a clinical trial conducted by Prager and colleagues, which tested the efficacy of trifluridine-tipiracil and bevacizumab in treating patients with refractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Multidisciplinary Sciences
Jinyao Shi, Zhouqiao Wu, Xiaolong Wu, Longtao Huangfu, Ting Guo, Xiaojing Cheng, Jing Han, Ziyu Li, Xiaofang Xing, Jiafu Ji
Summary: This study used multi-omics data of 2471 gastric cancer samples to identify glycometabolic subtypes and immune clustering subgroups of gastric cancer, and established a scoring system to predict the survival and response of chemotherapy and immunotherapy. The assessment of tumor glucose metabolism and immune microenvironment in gastric cancer has application value for predicting curative effects and formulating combined treatment strategies.
Article
Health Care Sciences & Services
Diana Cornelia Moisuc, Mihai Vasile Marinca, Andreea Mihaela Matei, Larisa Popovici, Petru Cianga
Summary: This prospective study aimed to evaluate the impact of chemotherapy and bevacizumab on the health-related quality of life of metastatic colorectal cancer patients. The results showed significant differences in functioning and symptoms after 6 months of treatment, with increased pain, nausea and vomiting, diarrhea, and decreased appetite. However, improvements in emotional function, cognitive function, and body image perception were also observed. Assessing the quality of life of these patients is crucial for identifying and treating symptoms related to cancer and therapy.
Article
Hematology
Johannes Bloehdorn, Julia Krzykalla, Karlheinz Holzmann, Andreas Gerhardinger, Billy Michael Chelliah Jebaraj, Jasmin Bahlo, Kathryn Humphrey, Eugen Tausch, Sandra Robrecht, Daniel Mertens, Christof Schneider, Kirsten Fischer, Michael Hallek, Hartmut Doehner, Axel Benner, Stephan Stilgenbauer
Summary: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab has been found to induce long-term remissions in patients with chronic lymphocytic leukemia. By using gene expression profiling and other prognostic parameters, integrative models can be developed to identify patients who specifically benefit from this treatment.
Review
Rehabilitation
Freerk T. Baumann, Nadine Reimer, Theresa Gockeln, Alexandra Reike, Michael Hallek, Christian Ricci, Eva M. Zopf, Daniela Schmid, Dennis Taaffe, Robert U. Newton, Daniel A. Galvao, Michael Leitzmann
Summary: Supervised pelvic floor muscle exercise (PFME) has been shown to significantly reduce postoperative urinary incontinence rates in prostate cancer patients. The effects of supervised PFME are most pronounced within the first 3 months post-surgery and higher intensity PFME in the first 6 months post-surgery. Unsupervised PFME has similar effects to no PFME in postoperative urinary incontinence.
DISABILITY AND REHABILITATION
(2022)
Article
Health Care Sciences & Services
Michael Kusch, Hildegard Labouvie, Vera Schiewer, Natalie Talalaev, Jan C. Cwik, Sonja Bussmann, Lusine Vaganian, Alexander L. Gerlach, Antje Dresen, Natalia Cecon, Sandra Salm, Theresia Krieger, Holger Pfaff, Clarissa Lemmen, Lisa Derendorf, Stephanie Stock, Christina Samel, Anna Hagemeier, Martin Hellmich, Bernd Leicher, Gregor Hueltenschmidt, Jessica Swoboda, Peter Haas, Anna Arning, Andrea Goettel, Kathrin Schwickerath, Ullrich Graeven, Stefanie Houwaart, Hedy Kerek-Bodden, Steffen Krebs, Christiana Muth, Christina Hecker, Marcel Reiser, Cornelia Mauch, Jennifer Benner, Gerdamarie Schmidt, Christiane Karlowsky, Gisela Vimalanandan, Lukas Matyschik, Lars Galonska, Annette Francke, Karin Osborne, Ursula Nestle, Markus Baeumer, Kordula Schmitz, Juergen Wolf, Michael Hallek
Summary: Germany is developing, implementing, and evaluating a new model of psycho-oncological care that aims to provide care to all cancer patients based on their individual needs. This model is being continuously improved and evaluated by an independent institution. The project aims to improve cross-sectoral care for cancer patients in Germany and explore its potential for integration into the healthcare system.
BMC HEALTH SERVICES RESEARCH
(2022)
Article
Oncology
Till Braun, Johanna Stachelscheid, Nadine Bley, Sebastian Oberbeck, Moritz Otte, Tony Andreas Muller, Linus Wahnschaffe, Markus Glass, Katharina Ommer, Marek Franitza, Birgit Gathof, Janine Altmueller, Michael Hallek, Daniel Auguin, Stefan Huettelmaier, Alexandra Schrader, Marco Herling
Summary: This study reveals the association of AGO2 gene with T-cell prolymphocytic leukemia (T-PLL) and its role in enhancing TCR signaling and promoting tumor growth. The findings highlight the importance of aberrant TCR signaling and provide potential therapeutic targets for T-PLL.
Review
Medicine, General & Internal
Michael Hallek, Axel Ockenfels, Daniel Wiesen
Summary: This article presents the findings of a selective literature review on the application of behavioral economics interventions to improve medical decision-making. It suggests that these interventions may help physicians make better decisions and enhance treatment outcomes, although more evidence on their long-term effects is needed.
DEUTSCHES ARZTEBLATT INTERNATIONAL
(2022)
Article
Oncology
Theophilos Tzaridis, Johannes Weller, Daniel Bachurski, Farhad Shakeri, Christina Schaub, Peter Hau, Andreas Buness, Uwe Schlegel, Joachim-Peter Steinbach, Clemens Seidel, Roland Goldbrunner, Niklas Schaefer, Robert J. Wechsler-Reya, Michael Hallek, Bjoern Scheffler, Martin Glas, Lothar Haeberle, Ulrich Herrlinger, Christoph Coch, Katrin S. Reiners, Gunther Hartmann
Summary: Evaluation of serum-derived extracellular vesicles (EVs) from glioblastoma patients reveals that the upregulation of CD29, CD44, CD81, C1QA, and histone H3 in serum EVs correlates with tumor progression, suggesting their potential as biomarkers.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Volker Arndt, Daniela Doege, Stefan Froehling, Peter Albers, Hana Alguel, Ralf Bargou, Carsten Bokemeyer, Martin Bornhaeuser, Christian H. Brandts, Peter Brossart, Sara Yvonne Brucker, Tim H. Bruemmendorf, Hartmut Doehner, Norbert Gattermann, Michael Hallek, Volker Heinemann, Ulrich Keilholz, Thomas Kindler, Cornelia von Levetzow, Florian Lordick, Ulf Peter Neumann, Christoph Peters, Dirk Schadendorf, Stephan Stilgenbauer, Thomas Zander, Daniel Zips, Delia Braun, Thomas Seufferlein, Gerd Nettekoven, Michael Baumann
Summary: The capacities of German Comprehensive Cancer Centers (CCCs) in various aspects of oncology care were significantly affected during the first 2 years of the COVID-19 pandemic. Follow-up, psycho-oncologic care, and tumor surgery were particularly impacted, along with other areas of multidisciplinary oncological care. This study highlights the importance of developing strategies to prevent similar limitations in the future.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Florian Simon, Adam Giza, Sandra Robrecht, Anna-Maria Fink, Paula Cramer, Julia von Tresckow, Moritz Fuerstenau, Valentin Goede, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Clemens-Martin Wendtner, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Othman Al-Sawaf
Summary: Patients aged 80 years and older with CLL have good outcomes when treated with targeted agents, although they are underrepresented in clinical trials.
LEUKEMIA & LYMPHOMA
(2022)
Article
Hematology
Jorge Garcia Borrega, Boris Boell, Matthias Kochanek, Jan-Hendrik Naendrup, Florian Simon, Noelle Sieg, Michael Hallek, Peter Borchmann, Udo Holtick, Alexander Shimabukuro-Vornhagen, Dennis A. Eichenauer, Jan-Michel Heger
Summary: A retrospective analysis was conducted on patients admitted to the intensive care unit (ICU) during hospitalization for high-dose chemotherapy and autologous stem cell transplantation (ASCT). The study found that the overall outcome was favorable for these patients.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Nadine Kutsch, Emily Eva Holmes, Sandra Robrecht, Gudrun Schueler, Ursula Vehling-Kaiser, Thomas Decker, Sigrun Mueller-Hagen, Karin Heinisch, Sebastian Boettcher, Matthias Ritgen, Karl-Anton Kreuzer, Stephan Stilgenbauer, Anna Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Clemens-Martin Wendtner
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Lavinia Arseni, Rakesh Sharma, Norman Mack, Deepthi Nagalla, Sibylle Ohl, Thomas Hielscher, Mahak Singhal, Robert Pilz, Hellmut Augustin, Roger Sandhoff, Christel Herold-Mende, Bjoern Tews, Peter Lichter, Martina Seiffert
Summary: A better understanding of tumor-stroma crosstalk and the role of sphingosine-1-phosphate (S1P) in mediating this crosstalk is crucial for the development of therapeutic approaches for human glioma. This study shows that higher levels of S1P result in an anti-inflammatory environment and inhibition of S1P signaling improves the anti-tumor response and overall survival in glioblastoma. These findings highlight the potential of targeting S1P as a therapeutic strategy.
Review
Physiology
Stephanie F. Preuss, Denise Grieshober, Hellmut G. Augustin
Summary: Proliferating cancer cells secrete factors that impact metabolism, interorgan communication, and tumor progression. These factors modulate endothelial cell activation, affecting tumor cell dissemination and the outgrowth of metastatic cells. Furthermore, endothelial cell signaling is involved in cancer-related metabolic symptoms, opening a new field of research. This review explores how these tumor-derived factors systemically affect endothelial cell signaling, activation, and impact distant organs as well as tumor progression.
Article
Oncology
Ruth Fluemann, Julia Hansen, Benedikt W. Pelzer, Pascal Nieper, Tim Lohmann, Ilmars Kisis, Tobias Riet, Viktoria Kohlhas, Phuong-Hien Nguyen, Martin Peifer, Nima Abedpour, Graziella Bosco, Roman K. Thomas, Moritz Kochanek, Jacqueline Knufer, Lorenz Jonigkeit, Filippo Beleggia, Alessandra Holzem, Reinhard Buttner, Philipp Lohneis, Jorn Meinel, Monika Ortmann, Thorsten Persigehl, Michael Hallek, Dinis Pedro Calado, Markus Chmielewski, Sebastian Klein, Joachim R. Goethert, Bjoern Chapuy, Branko Zevnik, F. Thomas Wunderlich, Bastian von Tresckow, Ron D. Jachimowicz, Ari M. Melnick, Hans Christian Reinhardt, Gero Knittel
Summary: Genomic profiling identified 5 subtypes of DLBCL, including the MCD/C5 cluster with MYD88, BCL2, PRDM1, and/or SPIB aberrations. Mouse models with B cell-specific Prdm1 or Spib aberrations were generated, showing molecular features of prememory and light-zone B cells. Combined BTK/BCL2 inhibition exhibited therapeutic activity in both mouse models and relapsed/refractory DLBCL patients.
BLOOD CANCER DISCOVERY
(2023)
Article
Medicine, General & Internal
L. Tometten, J. J. Malin, E. Pracht, P. J. Broeckelmann, C. Horn, R. Sprute, C. A. Langhorst, M. Hallek, G. Faetkenheuer, J. Rybniker
Summary: Immunodeficient patients with chronic and recurrent SARS-CoV-2 infections pose a significant health threat and present a major challenge in terms of treatment during the ongoing pandemic. Limited therapeutic options and emerging virus variants with immune escape mechanisms further complicate the medical care of these patients.
Meeting Abstract
Oncology
Othman Al-Sawaf, Can Zhang, Sandra Robrecht, Alex Kotak, Naomi Chang, Anna Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl Kreuzer, Brenda Chyla, Barbara Eichhorst, Yanwen Jiang, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
